diethylcarbamazine has been researched along with Recrudescence in 12 studies
Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although successful treatment of loiasis with diethylcarbamazine (DEC) has been reported, little is known about the long-term success rate of therapy or the predisposing factors for treatment failure." | 7.69 | Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. ( Klion, AD; Nutman, TB; Ottesen, EA, 1994) |
| "Although successful treatment of loiasis with diethylcarbamazine (DEC) has been reported, little is known about the long-term success rate of therapy or the predisposing factors for treatment failure." | 3.69 | Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. ( Klion, AD; Nutman, TB; Ottesen, EA, 1994) |
| " As compared to results from other studies with diethylcarbamazine and IVER at different dosages and periodicities, the dosage of IVER 400 seems the most effective; but a yearly intake might not be sufficient." | 2.67 | Long-term efficacy of single-dose treatment with 400 micrograms.kg-1 of ivermectin in bancroftian filariasis: results at one year. ( Cartel, JL; Chanteau, S; Glaziou, P; Martin, PM; Moulia-Pelat, JP; Nguyen, LN, 1993) |
| "The recurrences are common after such treatment." | 2.55 | New developments in chyluria after global programs to eliminate lymphatic filariasis. ( Abeygunasekera, AM; Balagobi, B; Sutharshan, K, 2017) |
| "Filariasis is an endemic problem in various Indian states." | 1.32 | Filarial chyluria: long-term experience of a university hospital in India. ( Dwivedi, US; Mahmood, M; Singh, H; Singh, PB; Tandon, V, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abeygunasekera, AM | 1 |
| Sutharshan, K | 1 |
| Balagobi, B | 1 |
| Tandon, V | 1 |
| Singh, H | 1 |
| Dwivedi, US | 1 |
| Mahmood, M | 1 |
| Singh, PB | 1 |
| Padigel, UM | 1 |
| Reddy, MV | 1 |
| Alikhan, A | 1 |
| Harinath, BC | 1 |
| Moulia-Pelat, JP | 1 |
| Glaziou, P | 1 |
| Nguyen, LN | 1 |
| Chanteau, S | 1 |
| Martin, PM | 1 |
| Cartel, JL | 1 |
| Klion, AD | 1 |
| Ottesen, EA | 1 |
| Nutman, TB | 1 |
| Shenoy, RK | 1 |
| Sandhya, K | 1 |
| Suma, TK | 1 |
| Kumaraswami, V | 1 |
| Ray, D | 1 |
| Zheng, HJ | 2 |
| Piessens, WF | 2 |
| Tao, ZH | 2 |
| Cheng, WF | 2 |
| Wang, SH | 2 |
| Cheng, SZ | 1 |
| Ye, YM | 2 |
| Luo, LF | 2 |
| Chen, XR | 2 |
| Gan, GB | 2 |
| Cheng, SH | 1 |
| Mann, JM | 1 |
| Heurich, AE | 1 |
| Ciferri, F | 1 |
| Glovsky, MM | 1 |
| Srinivas, HV | 1 |
| Antani, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection[NCT01111305] | Phase 2 | 31 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adverse events during the first week of DEC treatment (NCT01111305)
Timeframe: 7 days following initiation of DEC treatment
| Intervention | adverse events (Number) |
|---|---|
| Reslizumab + DEC | 29 |
| Placebo + DEC | 28 |
Peak eosinophil count during the first 7 days of treatment as a percent of the baseline count (NCT01111305)
Timeframe: during the first 7 days of DEC treatment
| Intervention | percent of baseline eosinophil count (Geometric Mean) |
|---|---|
| Reslizumab + DEC | 61 |
| Placebo + DEC | 245.6 |
serum eosinophil granule protein levels on day 7 measured as % baseline (NCT01111305)
Timeframe: one week
| Intervention | % change (Geometric Mean) | |
|---|---|---|
| % day 0 EDN at day 7 | % day 0 EPO at day 7 | |
| Placebo + DEC | 377 | 203 |
| Reslizumab + DEC | 115 | 138 |
(NCT01111305)
Timeframe: 3, 7, and 28 days after initiation of treatment with DEC
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 3 days | 7 days | 28 days | |
| Placebo | 2 | 4 | 4 |
| Reslizumab | 2 | 4 | 4 |
1 review available for diethylcarbamazine and Recrudescence
| Article | Year |
|---|---|
New developments in chyluria after global programs to eliminate lymphatic filariasis.
Topics: Animals; Chyle; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Glucose; Humans; Povidone- | 2017 |
4 trials available for diethylcarbamazine and Recrudescence
| Article | Year |
|---|---|
Long-term efficacy of single-dose treatment with 400 micrograms.kg-1 of ivermectin in bancroftian filariasis: results at one year.
Topics: Animals; Diethylcarbamazine; Elephantiasis, Filarial; Female; Follow-Up Studies; Humans; Ivermectin; | 1993 |
A preliminary study of filariasis related acute adenolymphangitis with special reference to precipitating factors and treatment modalities.
Topics: Adolescent; Adult; Aged; Animals; Anti-Bacterial Agents; Brugia; Causality; Diethylcarbamazine; Elep | 1995 |
[Efficacy of ivermectin for control of microfilaremia recurring after treatment with diethylcarbamazine. I. Clinical and parasitological observations].
Topics: Adolescent; Adult; Aged; Animals; Diethylcarbamazine; Double-Blind Method; Elephantiasis, Filarial; | 1992 |
Efficacy of ivermectin for control of microfilaremia recurring after treatment with diethylcarbamazine. I. Clinical and parasitologic observations.
Topics: Adolescent; Adult; Animals; Diethylcarbamazine; Double-Blind Method; Elephantiasis, Filarial; Female | 1991 |
7 other studies available for diethylcarbamazine and Recrudescence
| Article | Year |
|---|---|
Filarial chyluria: long-term experience of a university hospital in India.
Topics: Adolescent; Adult; Chyle; Diet, Fat-Restricted; Diethylcarbamazine; Female; Filariasis; Filaricides; | 2004 |
Immunomonitoring of filarial patients during DEC therapy in an endemic area: a seven-year follow-up.
Topics: Animals; Antibodies, Helminth; Antigens, Helminth; Diethylcarbamazine; Enzyme-Linked Immunosorbent A | 1995 |
Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up.
Topics: Diethylcarbamazine; Follow-Up Studies; Humans; Loiasis; Recurrence; Travel | 1994 |
Relapsing tropical eosinophilia.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eosinophilia; Female; Humans; Lung Diseases, Parasitic | 1977 |
Response of diffusion capacity in the treatment of tropical eosinophilia.
Topics: Adult; Carbon Dioxide; Diethylcarbamazine; Diffusion; Female; Forced Expiratory Volume; Humans; Lung | 1991 |
Chronic chyluria: a clinical study of 3 patients.
Topics: Adult; Blood Pressure; Body Height; Body Weight; Chronic Disease; Chyle; Diethylcarbamazine; Female; | 1985 |
Recurrent gross achylous hematuria of filarial etiology (report of 5 cases).
Topics: Adolescent; Adult; Diethylcarbamazine; Female; Filariasis; Hematuria; Humans; Male; Recurrence | 1973 |